Holen Sie sich die Stockscreener-App
28.00
4.28%
1.15
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsAGIO - ACCESS Newswire
Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date - The Globe and Mail
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Agios Pharma stock awaits FDA decision on Pyrukynd as PDUFA date passes - Investing.com UK
Marshall Wace LLP Purchases 163,796 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals' Supplemental NDA for Mitapivat to Treat Thalassemia Still Under FDA Review - marketscreener.com
Agios shares slide after FDA misses decision deadline on mitapivat application - MSN
Agios Pharmaceuticals (AGIO) Awaits FDA Decision on Mitapivat Ap - GuruFocus
Agios Pharmaceuticals says FDA has not issued decision on Agios' sNDA for mitapivat - marketscreener.com
Agios Pharma falls after FDA misses decision deadline on blood-disorder drug filing - TradingView
FDA delays decision on Agios’ thalassemia drug application By Investing.com - Investing.com UK
Agios Pharmaceuticals Provides Update on FDA Review Status for Supplemental New Drug Application of Mitapivat for Thalassemia - Quiver Quantitative
Agios stock falls after FDA delays decision on thalassemia drug By Investing.com - Investing.com UK
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - The Manila Times
Agios (Nasdaq: AGIO) says FDA mitapivat thalassemia sNDA still under review after Dec. 7 PDUFA goal date - Stock Titan
(AGIO) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Agios Faces A Make-Or-Break Year As Key Drug Decisions Loom - Finimize
How The Latest Trial And FDA Risk Shift The Story For Agios Pharmaceuticals - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC (AGIO) Investigation: Bronstei - The National Law Review
How Agios Pharmaceuticals Inc. (8AP) stock trades pre earningsMarket Movement Recap & Daily Profit Focused Stock Screening - Newser
Will Agios Pharmaceuticals Inc. (8AP) stock hit analyst forecasts2025 Support & Resistance & Fast Gaining Stock Reports - Newser
Why Agios Pharmaceuticals Inc. (8AP) stock stays on buy listsPortfolio Update Report & Growth Oriented Trading Recommendations - Newser
How analysts rate Agios Pharmaceuticals Inc. stock todayPortfolio Gains Report & Daily Technical Forecast Reports - Newser
Why Agios Pharmaceuticals Inc. (8AP) stock appears on watchlists2025 Historical Comparison & Real-Time Stock Entry Alerts - Newser
Why Agios Pharmaceuticals (AGIO) Is Down 7.1% After Phase 3 Sickle Cell Win With Mitapivat - Sahm
Europe Autoimmune Hemolytic Anemia Therapeutics Market to hit - openPR.com
How cyclical is Agios Pharmaceuticals Inc. (8AP) stock compared to rivalsJuly 2025 Opening Moves & Low Risk Investment Opportunities - Newser
Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight - GlobeNewswire Inc.
Fisher Asset Management LLC Sells 81,799 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Is Agios Pharmaceuticals Inc. (8AP) stock a top dividend aristocrat candidateWeekly Trading Summary & Weekly Return Optimization Plans - Newser
Published on: 2025-12-03 01:52:18 - Newser
Prudential Financial Inc. Lowers Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
How Agios Pharmaceuticals Inc. (8AP) stock gains from tech spending2025 Breakouts & Breakdowns & Fast Entry and Exit Trade Plans - Newser
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst - MSN
How Agios Pharmaceuticals Inc. (8AP) stock moves on employment dataMarket Risk Summary & Growth Focused Investment Plans - Newser
Published on: 2025-12-02 00:03:25 - Newser
Is Agios Pharmaceuticals Inc a good long term investmentPortfolio Risk Assessment & Minimal Capital Trading Tips - earlytimes.in
Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded by Citigroup to Strong-Buy Rating - MarketBeat
How Agios Pharmaceuticals Inc. stock reacts to Fed rate cutsJuly 2025 Chart Watch & Verified Stock Trade Ideas - BỘ NỘI VỤ
How Agios Pharmaceuticals Inc. stock valuations compare to rivals2025 Biggest Moves & Long Hold Capital Preservation Tips - BỘ NỘI VỤ
A Look at Agios Pharmaceuticals (AGIO) Valuation Following Strong Phase 3 Sickle Cell Trial Results - Sahm
Envestnet Asset Management Inc. Reduces Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Aug Intraday: How strong is Agios Pharmaceuticals Inc. stock balance sheet2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - moha.gov.vn
Agios Pharmaceuticals Inc Stock Analysis and ForecastDividend Aristocrats List & Trusted Financial Advisors at No Cost - earlytimes.in
Intech Investment Management LLC Sells 12,496 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
FY2026 EPS Estimates for AGIO Increased by Cantor Fitzgerald - MarketBeat
Geode Capital Management LLC Boosts Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Does Agios Pharmaceuticals Inc. (8AP) stock trade below intrinsic valueTreasury Yields & Stock Portfolio Risk Management - moha.gov.vn
Citigroup Initiates Coverage on AGIO with a Buy Rating | AGIO St - GuruFocus
Is Agios Pharmaceuticals Inc. stock a safe haven assetProfit Target & Long Hold Capital Preservation Plans - BỘ NỘI VỤ
(AGIO) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Agios falls after mixed data from late-stage trial for sickle cell therapy - MSN
Agios Beats Revenue Forecasts And Eyes PYRUKYND’s Future - Finimize
Agios Pharmaceuticals (NASDAQ:AGIO) Coverage Initiated at Truist Financial - MarketBeat
Why Agios Pharmaceuticals (AGIO) May See Shifting Fortunes After Strong Phase 3 Sickle Cell Data - Sahm
Truist Securities initiates coverage on Agios Pharma stock with Buy rating - Investing.com Canada
Truist Securities Initiates Coverage on Agios Pharmaceuticals (A - GuruFocus
What is HC Wainwright's Estimate for AGIO FY2025 Earnings? - MarketBeat
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):